Rachel A. Hodge
Université Paris-Sud
1 paper in the Anchorcite directory, published in 2017, cited 5,640 times in total.
ORCID profileResearch topics
- HER2/EGFR in Cancer Research · 1 paper
- Lung Cancer Diagnosis and Treatment · 1 paper
- Lung Cancer Treatments and Mutations · 1 paper
Frequent co-authors
- Jean‐Charles Soria · 1 paper
- Yuichiro Ohe · 1 paper
- Johan Vansteenkiste · 1 paper
- Thanyanan Reungwetwattana · 1 paper
- Busayamas Chewaskulyong · 1 paper
- Ki Hyeong Lee · 1 paper
- Arunee Dechaphunkul · 1 paper
- Fumio Imamura · 1 paper
Papers
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 5,640 citations
BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell…
Metadata from OpenAlex (CC0).